“… Just a heads up on an event that seems to be flying completely under the radar next week: Dr. Wolfgang Liedtke will be delivering an oral presentation, “Exploring Treatment for Older Adults with Pre-Frailty to Mitigate Cognitive and Physical Decline Targeting Autophagy with Oral Blarcamesine”, next Thursday at the ICFSR26 Conference at Johns Hopkins.
While the market is understandably hyper-focused on the pending EMA Alzheimer’s re-exam, I think it’s a mistake to ignore the broader strategic signal Anavex is sending here. By moving toward a pre-frailty indication, they are actively shifting the narrative from a narrow CNS treatment to a platform for systemic geroprotection—effectively establishing blarcamesine as an intervention designed to slow the fundamental biological wear and tear of aging….”
Market Data 
Markets 
AI
